Literature DB >> 29250166

Reactivity of thyroid papillary carcinoma cells to thyroid stimulating hormone-dominated endocrine therapy.

Yuqin Ma1, Xia Zhang1, Yutao Wang1.   

Abstract

This study investigated the effect of thyroid stimulating hormone (TSH) on the proliferation of papillary thyroid carcinoma (PTC) cells and the therapeutic effect of levothyroxine sodium (TH). PTC cells (TPC-1) were cultured using 0.1, 1.0 and 10 U/l TSH and 10-2, 10-4 and 10-6 mol/l TH. After the appropriate concentration was screened, TPC-1 cells were further divided into control group, TSH group, TH group and TSH+TH group. The cell proliferation was detected via methyl thiazolyl tetrazolium (MTT) method, TPC-1 cell cycle was detected via flow cytometer, and the mRNA and protein expression of cyclin D1 were detected via real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Compared with control group, TSH significantly promoted the proliferation of TPC-1 cells (P<0.05 or P<0.01), obviously promoted the transition of TPC-1 cells from G1 phase to S phase (P<0.01) and remarkably increased the mRNA and protein expression of cyclin D1 (P<0.01); but TH had a significant inhibitory effect on these results of TSH (P<0.05 or P<0.01). TSH can promote the proliferation of PTC cells, and the appropriate complement of TH can inhibit its proliferation.

Entities:  

Keywords:  cell proliferation; cyclin D1; papillary thyroid carcinoma cell; thyroid stimulating hormone; thyroxine

Year:  2017        PMID: 29250166      PMCID: PMC5727597          DOI: 10.3892/ol.2017.7173

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

Review 1.  Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma.

Authors:  M R Pelizzo; I Merante Boschin; A Toniato; C Pagetta; E Casal Ide; C Mian; D Rubello
Journal:  Minerva Endocrinol       Date:  2008-12       Impact factor: 2.184

2.  Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?

Authors:  G Brabant
Journal:  J Clin Endocrinol Metab       Date:  2008-04       Impact factor: 5.958

Review 3.  The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology.

Authors:  D Glinoer
Journal:  Endocr Rev       Date:  1997-06       Impact factor: 19.871

4.  Thyroid papillary carcinoma after alemtuzumab therapy for MS.

Authors:  Richard Ibitoye; Alastair Wilkins
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

5.  Thyrotropin serum concentrations in patients with papillary thyroid microcancers.

Authors:  Marion Gerschpacher; Christian Göbl; Christian Anderwald; Alois Gessl; Michael Krebs
Journal:  Thyroid       Date:  2010-04       Impact factor: 6.568

6.  Mapping of a major susceptibility locus for Graves' disease (GD-1) to chromosome 14q31.

Authors:  Y Tomer; G Barbesino; M Keddache; D A Greenberg; T F Davies
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

7.  Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.

Authors:  T-R Liu; X Su; W-S Qiu; W-C Chen; Q-Q Men; L Zou; Z-Q Li; X-Y Fu; A-K Yang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-09       Impact factor: 3.507

8.  Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience.

Authors:  Sang Soo Kim; Byung Joo Lee; Jin Choon Lee; Sang Heon Song; Bo Hyun Kim; Seok Man Son; In Ju Kim; Yong Ki Kim; Yang Ho Kang
Journal:  Endocrine       Date:  2010-12-14       Impact factor: 3.633

9.  High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.

Authors:  Pankaj G Roy; Norman Pratt; Colin A Purdie; Lee Baker; Alison Ashfield; Phil Quinlan; Alastair M Thompson
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

10.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

View more
  1 in total

1.  The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement.

Authors:  Bambang Udji Djoko Rianto; Anton Sony Wibowo; Camelia Herdini
Journal:  Int Arch Otorhinolaryngol       Date:  2019-11-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.